These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
531 related articles for article (PubMed ID: 32243501)
1. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Zhang X; Song K; Tong F; Fei M; Guo H; Lu Z; Wang J; Zheng C Blood Adv; 2020 Apr; 4(7):1307-1310. PubMed ID: 32243501 [TBL] [Abstract][Full Text] [Related]
2. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report. Michot JM; Albiges L; Chaput N; Saada V; Pommeret F; Griscelli F; Balleyguier C; Besse B; Marabelle A; Netzer F; Merad M; Robert C; Barlesi F; Gachot B; Stoclin A Ann Oncol; 2020 Jul; 31(7):961-964. PubMed ID: 32247642 [No Abstract] [Full Text] [Related]
3. Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab. De Luna G; Habibi A; Deux JF; Colard M; Pham Hung d'Alexandry d'Orengiani AL; Schlemmer F; Joher N; Kassasseya C; Pawlotsky JM; Ourghanlian C; Michel M; Mekontso-Dessap A; Bartolucci P Am J Hematol; 2020 Jul; 95(7):876-878. PubMed ID: 32282956 [No Abstract] [Full Text] [Related]
5. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma. Chaidos A; Katsarou A; Mustafa C; Milojkovic D; Karadimitris A Br J Haematol; 2020 Jul; 190(1):e9-e11. PubMed ID: 32369612 [No Abstract] [Full Text] [Related]
6. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia. Ranger A; Haji R; Kaczmarski R; Danga A Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422 [No Abstract] [Full Text] [Related]
7. Vascular microthrombosis associated with increased interleukin-6. A severe acute respiratory distress syndrome in COVID-19 patients treated with tocilizumab. Mohebbi N; Abedini A; Lashgari R; Razavi F; Varahram M; Kiani A Adv Respir Med; 2020; 88(5):468-469. PubMed ID: 33169824 [No Abstract] [Full Text] [Related]
8. [First case of COVID-19 treated with tocilizumab in Iceland]. Bjornsson AH; Olafsdottir T; Thormar KM; Kristjansson M; Thorisdottir AS; Ludviksson BR; Guðmundsson S; Gottfredsson M Laeknabladid; 2020 Mai; 106(5):247-250. PubMed ID: 32367812 [TBL] [Abstract][Full Text] [Related]
9. Audio Interview: Tocilizumab and Covid-19. Rubin EJ; Baden LR; Morrissey S N Engl J Med; 2020 Oct; 383(17):e114. PubMed ID: 33085870 [No Abstract] [Full Text] [Related]
10. Treatment considerations for patients with pemphigus during the COVID-19 pandemic. Shakshouk H; Daneshpazhooh M; Murrell DF; Lehman JS J Am Acad Dermatol; 2020 Jun; 82(6):e235-e236. PubMed ID: 32283243 [No Abstract] [Full Text] [Related]
11. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient. Allam SR; Dao A; Madhrira MM; Antiporta PB; Nair RR; Guiteau JJ; Reyad AI Transpl Infect Dis; 2020 Aug; 22(4):e13326. PubMed ID: 32406985 [No Abstract] [Full Text] [Related]
12. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience. Jiménez-Brítez G; Ruiz P; Soler X Med Clin (Barc); 2020 Nov; 155(9):410-411. PubMed ID: 32718713 [No Abstract] [Full Text] [Related]
13. Tocilizumab in the treatment of a critical COVID-19 patient: a case report. Wang L; Peng X; Wang ZH; Cai J; Zhou FC Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5783-5787. PubMed ID: 32495916 [TBL] [Abstract][Full Text] [Related]
14. Tocilizumab administration in a refractory case of COVID-19. Dastan F; Nadji SA; Saffaei A; Tabarsi P Int J Antimicrob Agents; 2020 Aug; 56(2):106043. PubMed ID: 32502524 [No Abstract] [Full Text] [Related]
15. May IL-17 have a role in COVID-19 infection? Megna M; Napolitano M; Fabbrocini G Med Hypotheses; 2020 Jul; 140():109749. PubMed ID: 32339777 [No Abstract] [Full Text] [Related]
16. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far? Zhang Y; Zhong Y; Pan L; Dong J Drug Discov Ther; 2020; 14(2):100-102. PubMed ID: 32378647 [TBL] [Abstract][Full Text] [Related]
17. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Della-Torre E; Campochiaro C; Cavalli G; De Luca G; Napolitano A; La Marca S; Boffini N; Da Prat V; Di Terlizzi G; Lanzillotta M; Rovere Querini P; Ruggeri A; Landoni G; Tresoldi M; Ciceri F; Zangrillo A; De Cobelli F; Dagna L; ; Ann Rheum Dis; 2020 Oct; 79(10):1277-1285. PubMed ID: 32620597 [TBL] [Abstract][Full Text] [Related]
19. Preemptive interleukin-6 blockade in patients with COVID-19. Guillén L; Padilla S; Fernández M; Agulló V; García JA; Telenti G; García-Abellán J; Botella Á; Gutiérrez F; Masiá M Sci Rep; 2020 Oct; 10(1):16826. PubMed ID: 33033405 [TBL] [Abstract][Full Text] [Related]
20. Early tocilizumab treatment could improve survival among COVID-19 patients. Campins L; Boixeda R; Perez-Cordon L; Aranega R; Lopera C; Force L Clin Exp Rheumatol; 2020; 38(3):578. PubMed ID: 32456769 [No Abstract] [Full Text] [Related] [Next] [New Search]